98% simvastatin Pharmaceutical Grade cas 79902-63-9

Superiority:

This product is hydroxymethyl glutaryl-coa (HMG-COA) reductase inhibitor, inhibits the synthesis of endogenous cholesterol, for lipid regulator. Literature shows that it can reduce the content of total cholesterol (TC) in serum, liver and aorta of hyperlipidemia rabbits, and reduce the level of very low density lipoprotein cholesterol (VLDL-C) and low density lipoprotein cholesterol (LDL-C).

1. Hyperlipidemia

(1) Simvastatin may be used to reduce elevated total cholesterol, LDL cholesterol, apolipoprotein B, and triglycerides in patients with primary hypercholesterolemia, heterozygous familial hypercholesterolemia, or mixed hypercholesterolemia when dietary control and other nonpharmacologic treatments are unsatisfactory. And simvastatin increases HDL cholesterol, thereby lowering the LDL/HDL and total cholesterol/HDL ratios.

(2) For homozygous familial hypercholesterolemia, simvastatin can be used to reduce elevated total cholesterol, low density lipoprotein cholesterol, and apolipoprotein B when dietary control and non-dietary therapy are unsatisfactory.

2, coronary heart disease. For patients with coronary heart disease, simvastatin is used for:

(1) Reduce the risk of death.

(2) Reduce the risk of death from coronary heart disease and non-fatal myocardial infarction.

(3) Reduce the risk of stroke and transient cerebral ischemia.

(4) Reduce the risk of myocardial recanalization operations (coronary artery bypass grafting and percutaneous balloon coronary angioplasty).

(5) Delay the progression of atherosclerosis, including the occurrence of new lesions and total blockage.